632 A phase 1/2 open label study of LabVax 3(22)-23 and adjuvant GM-CSF alone or in combination with pembrolizumab in subjects with labyrinthin-positive adenocarcinomas

632 A phase 1/2 open label study of LabVax 3(22)-23 and adjuvant GM-CSF alone or in combination with pembrolizumab in subjects with labyrinthin-positive adenocarcinomas

Bibliographic Details
Main Authors: Shuai Chen, Tianhong Li, Weijie Ma, Tingting Lu, Siqi Long, Kyra A Toomey, Michael Babich, Colleen Pineda, Laura Molnar, Leslie Garcia, Kit Tam, Rashmi Verma, Chihong Zhou, Nancy Ogilhara
Format: Article
Language:English
Published: BMJ Publishing Group 2023-11-01
Series:Journal for ImmunoTherapy of Cancer

Similar Items